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Abstract: In the broadest context, biological markers, or biomarkers, are molecules that 
characterize a biological system or process. In the setting of cardiovascular disease, a number 
of biomarkers have become an integral part of diagnostic and risk stratification strategies. In 
this review, we will discuss classic and emerging biomarkers of cardiovascular disease and 
the role of these biomarkers in the diagnosis and prognosis of elderly patients presenting with 
acute myocardial infarction.
Keywords: cardiovascular disease, biological markers, diagnosis, prognosis
Acute coronary syndromes in the elderly
Ischemic heart disease (coronary artery disease, angina pectoris, and myocardial 
 infarction) is commonly encountered in the current medical era. Data from the 
2007–2010 National Health and Nutrition Examination Survey suggests 6.4% of all 
Americans .20 years old (15.4 million adults) have some form of ischemic heart 
 disease. Not surprisingly, the prevalence of symptomatic ischemic heart disease 
increases with age. United States census data for 2012 revealed a total population of 
313 million persons, with 61 million (∼20%) being categorized as elderly ($60 years).1 
Of these individuals, about 21% of men and 11% of women aged 60–79 years 
have ischemic heart disease; the numbers jump to 35% of men and 19% of women 
aged $80 years. In the United States, 180,000 men and 210,000 women over the age 
of 75 suffer an acute myocardial infarction (AMI) or die from coronary heart disease 
every year. The estimated direct and indirect cost of ischemic heart disease was $195.2 
billion in 2009. This number is projected to increase ∼100% from 2013 to 2030.2
Biomarkers of myocardial necrosis
In the broadest context, biological markers, or biomarkers, are molecules that charac-
terize a biological system or process. They are measured in a variety of situations and 
may indicate normal physiology, identify pathologic states, or be used to monitor a 
therapeutic response. Ideally, biomarkers affect therapy by identifying patients likely 
to benefit from a therapeutic intervention or in whom a more aggressive diagnostic 
strategy should be undertaken. In the setting of cardiovascular disease (CVD), biomark-
ers, particularly cardiac troponins (cTn) have become an integral part of diagnostic 
strategies. Other biomarkers alone or in combination have been shown to identify 
patients at high risk for subsequent adverse outcomes, but have not been shown to 
predict a response to a particular therapeutic strategy.
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Traditionally, creatinine kinase (CK), lactate  dehydrogenase, 
and aspartate aminotransferase were used to evaluate for myo-
cardial damage among patients presenting with chest pain. 
While sensitive for detecting cellular death, these  biomarkers 
lacked specificity for myocardial injury. Later, the myocardial 
band (MB) isoform of CK (CK-MB) and serum myoglobin 
levels were utilized to improve specificity for cardiac damage 
and reduce the time to diagnosis (Figure 1). In the last two 
decades, the measurement of serum troponin level has become 
the predominant biomarker for the detection of myocardial 
necrosis. In this review, we will discuss the evolution of tro-
ponin as the quintessential biomarker for the diagnosis of AMI. 
We will also discuss newer biomarkers being evaluated as part 
of a multimarker approach for the diagnosis of AMI.
Serum troponin  
and the diagnosis of AMI
Cardiac troponin I (cTnT) and troponin I (cTnI) are both 
structural proteins found in the contractile apparatus of 
cardiac myocytes (Figure 1). Both of these molecules are 
coded by single genes that are not expressed outside of the 
cardiac myocyte. In the myocyte, troponin is found in two 
“pools”; the majority (∼95%) is bound to actin filaments in 
the sarcomere and is released into the systemic circulation 
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Figure 1 The cardiac sarcomere showing the sites at which troponin T and I are active.
Notes: The temporal release pattern of the classic biomarkers of myocardial infarction including cTnT, cTnI, CK-MB, myoglobin, and LD1. Reprinted with permission 
from Lippincott williams & wilkins/wolters Kluwer Health: Anesthesiology. Archan S, Fleisher LA. From creatine kinase-MB to troponin: the adoption of a new standard. 
112(4):1005–1012.50 Copyright © 2010 wolters Kluwer Health. Promotional and commercial use of the material in print, digital or mobile device format is prohibited without 
the permission from the publisher Lippincott williams & wilkins. Please contact journalpermissions@lww.com for further information.
Abbreviations: AMI, acute myocardial infarction; CK-MB, creatine kinase myocardial band; cTnI, cardiac troponin I; cTnT, cardiac troponin T; LD1, lactate dehydrogenase 1.
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when the myocyte dies. The “cytoplasmic” or “early appear-
ing” pool of  troponin is unbound and can be released into the 
circulation in the absence of cell death.3 Myocyte damage 
and cell death induces release of the “early pool” of cTn fol-
lowed by release of the bound troponin. Levels usually peak 
12–24 hours after injury, but may be present in circulation 
for weeks following a large AMI.4
Early studies identified troponin as a more sensitive 
marker of AMI than CK-MB.5 Subsequently, “troponin 
positive”, CK-MB “negative” patients were found to be at 
substantial short-term risk for recurrent myocardial  infarction 
and mortality.6 Most importantly, troponin elevation alone 
was found to identify patients likely to benefit from  intensive 
antiplatelet therapy or an early invasive management strat-
egy.7,8 Eventually, elevated troponin levels were included in 
risk stratification schemes such as the TIMI-Risk Score and 
the GRACE-Risk Score.9,10
The universal diagnosis of AMI
The importance of cTn in the diagnosis and management of 
AMI was recently underscored by the development of a new 
“definition” of myocardial infarction. This universal defini-
tion of myocardial infarction is based on the detection of a 
rise and fall in troponin, with at least one value greater than 
the 99th percentile of the upper reference limit (URL) for 
the assay. This biomarker elevation must be accompanied 
with at least one of the following: symptoms suggestive of 
ischemia, new or presumed new ST changes of left bundle 
branch block, pathological Q-waves, imaging that indicates 
the loss of viable myocardium or a new regional wall motion 
abnormality, or identification of intracoronary thrombus at 
autopsy.11 With the advent and, now, routine use of biomark-
ers, the definition of an AMI has been transformed from a 
clinical diagnosis supported by electrocardiogram findings 
and biomarkers to a biomarker measurement supported by 
electrocardiogram and clinical findings.12
Troponin assays
There are several commercially available cTnI assays, 
but cTnT assays are produced by a single manufacturer. 
These assays are based on the affinity of an antibody for an 
epitope on the troponin molecule and vary significantly with 
respect to clinical performance, making it essential to under-
stand the test characteristics of the specific product being 
used. To date, there is no agreement regarding the reference 
population used to characterize a particular assay; therefore, 
variability with respect to age, sex, and ethnicity is to be 
expected. Ideally, each hospital laboratory would perform 
reference testing independently to determine the precision 
of the assay and local “cutoff ” points. This is generally not 
possible, and so a reliance on published values for reference 
limits and reliability exists.
In general, there are three characteristics of troponin 
assays that should be considered. The point at which a 
troponin concentration is deemed abnormal or “elevated” 
is based on a determination of the 99th percentile URL for 
a given assay. Using this definition, the risk that a healthy 
person, selected at random from the general population, has 
an abnormal troponin level is 0.01 (1%). The coefficient of 
variability (CV) is a measure of the imprecision of a labora-
tory test if the same sample were repeatedly analyzed. With 
respect to serum troponin assays, a CV of ,10% is consid-
ered ideal, and an assay with a CV of .20% should not be 
utilized, in general.11 A CV between 10% and 20% may be 
of use, but may be associated with a few more misclassifica-
tions at low troponin concentrations.13 An ideal assay would 
then be characterized by a CV of ,10% at the 99th percentile 
URL. Unfortunately, contemporary troponin assays are at the 
limits of their detection at low troponin levels and are often 
unable to deliver precise measurements at or below the 99th 
percentile URL (CV .20%). In such situations, it has been 
recommended that a cutoff be set at the lowest point that can 
be measured with a CV of ,10%.14 Regardless, a solitary 
elevation in cTnI or cTnT is considered insufficient for 
the diagnosis of AMI. In most cases, serial measurements 
drawn 3–6 hours apart are performed, and the diagnosis of 
AMI is established when a rise and fall in the level of cTnI 
or cTnT is detected.11
Troponin elevations outside  
the setting of AMI
It is important to note that the evidence substantiating the 
role of troponin in the diagnosis of AMI arises from studies 
in which the subjects had a relatively high pretest probability 
of having coronary artery disease and AMI. As with any 
diagnostic test, the reliability of the test decreases consider-
ably when used in situations in which AMI is unlikely. At 
the time of development, it was hoped that elevations in cTn 
would be sensitive, but perhaps more importantly, exquisitely 
specific for myocardial injury.15 Unfortunately, experience 
with these assays has demonstrated numerous situations in 
which “elevated” cTn levels do not signal AMI.  Specifically, 
it is known that patients with renal failure or chronic systolic 
or diastolic heart failure (HF) can have a persistently elevated 
cTn.16–18 Additionally, it has been noted that an elevated cTn 
can be associated with other life-threatening conditions such as 
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aortic dissection, pulmonary embolism, and sepsis.19–21 Despite 
this lack of specificity, the test is frequently ordered. In one 
analysis, a serum troponin level was ordered in 48% of patients 
presenting to an emergency department, only 29% of whom 
were admitted to “rule out” a myocardial infarction.22 Thus, it 
has become common for a cardiologist to be asked to evaluate 
a patient simply because of “an elevated troponin”.23,24
Troponin elevations in the elderly
The current generation of troponin assays is poorly studied 
among elderly patients. The studies that established troponin 
as the diagnostic standard for AMI enrolled relatively young 
patients with a high pretest probability of AMI.6  Subsequent 
studies have found troponin elevations in “apparently healthy” 
subjects, especially those that are elderly. For example, in 
the Prospective Investigation of the Vasculature in Uppsala 
Seniors (PIVAS) study, 1,005 persons 70 years of age were 
evaluated for the presence of elevated cTnI levels. Using 
an assay with a lower limit of detection of 0.006 µg/L and 
 “abnormal” cutoff value of 0.01 µg/L, the authors found that 
21.8% of these patients had an elevated cTnI level.  Predictors 
of elevated cTnI included the male sex, cardiac risk factors, 
and impaired left ventricular systolic function.25 In  contrast, 
in the Dallas Heart Study (DHS), 3,557 patients aged 
30–65 years underwent a test for serum troponin using a cTnT 
assay with a lower detection limit of 0.01 µg/L. A detectable 
troponin level was found in only 1% of these younger subjects 
(0.7%; confidence interval 0.3%–1.1%).26 Thus, the diagnostic 
characteristics of the traditional troponin assays among elderly 
subjects remains to be definitively determined.
Multiple biomarkers  
for the diagnosis of AMI
The increasing sensitivity of troponin makes it unlikely 
another marker of myocardial necrosis will add considerably 
to diagnostic or prognostic algorithms for AMI. However, 
there are still patients in whom troponin levels at presentation 
are undetectable and who proceed to be diagnosed with an 
AMI. Recently, diagnostic strategies using a combination of 
biomarkers have been evaluated in hope of identifying high 
risk patients with chest pain. The combination of troponin 
and a biomarker that does not arise from myocardial necrosis 
but by a different mechanism such as myocardial stretch, 
inflammation, or stress is appealing.
Natriuretic peptides
Brain natriuretic peptide (BNP) is a natriuretic hormone pro-
duced by myocytes and was initially identified in the brain. 
A prohormone is released in response to increased wall 
tension or myocardial stretch. Cleavage of the prohormone 
in circulation releases BNP and the more stable N-terminal 
fragment (NT-proBNP). Plasma concentrations of both of 
these hormones are elevated in patients with left ventricular 
dysfunction (systolic or diastolic) and are frequently used 
to aid in the diagnosis of clinical HF.27 The measurement 
of NT-proBNP and BNP levels have become commonplace 
in the setting of HF. It has become evident, however, that 
NT-proBNP and BNP levels are also elevated in a variety 
of other situations associated with myocardial dysfunc-
tion, such as pulmonary embolism, sepsis, and myocardial 
infarction.28–30
BNP and NT-proBNP in the elderly
Plasma concentrations of BNP and NT-proBNP increase with 
increasing age. In fact, age appears to be the most important 
independent variable in explaining plasma levels of BNP and 
NT-proBNP.31,32 The reason for this increase is not entirely 
clear. Initial investigations suggested cardiac structural 
alterations (increased left ventricular mass, increased left 
atrial volume) and reduced renal clearance of the natriuretic 
peptides with aging. However, when BNP was studied in a 
population of more than 700 normal subjects in sinus rhythm 
without cardiovascular disease, renal disease, pulmonary 
disease, or diabetes, on no cardiovascular medications, and 
with normal cardiac function, age was still an independent 
predictor of BNP levels.32
C-reactive protein
Inflammation plays a central role in the development of 
atherosclerosis. C-reative protein (CRP) is a marker of 
inflammation. Elevations in CRP, especially when measured 
using highly sensitive assays (hs-CRP) have been shown to 
predict the presence of coronary disease among apparently 
healthy subjects and to predict adverse events in the setting 
of AMI.33,34
Multimarker strategies
The potential of serum cTnI, BNP, and hs-CRP to predict 
outcomes in AMI was established by evaluating blood 
samples collected from a subset of patients enrolled in a large 
clinical trial. Samples were drawn in 450 patients within 
72 hours of presentation with AMI and sent to a core lab 
for analysis. Multivariable analysis indicated each of these 
biomarkers was an independent predictor of subsequent 
adverse  outcomes including death, recurrent myocardial 
infarction, and the development of HF. A scoring system 
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was developed that reflected the number of biomarkers that 
were elevated. The risk of mortality, recurrent myocardial 
infarction, or HF at 30 days increased in proportion to the 
number of biomarkers that were elevated. This scoring sys-
tem was then validated in a larger cohort of patients enrolled 
in another clinical trial.35
The prognostic utility of NT-proBNP, hs-CRP, and cTnT 
and several other candidate biomarkers has been studied in 
a group of patients presenting with chest pain. Both NT-
proBNP and cTnT, but not hs-CRP, emerged as independent 
predictors of adverse events in the year following presenta-
tion (Figure 2). An elevated NT-proBNP ($1,371 ng/L) was 
associated with an adjusted odds ratio of 2.7 for death or AMI 
at 1 year. When the concentration of both NT-proBNP and 
cTnT exceeded the cutoff values, the risk of death or AMI 
at 1 year was 11.9% compared with 1.4% among patients in 
whom neither biomarker was elevated.36
Future perspectives – emerging 
biomarkers
The next generation of troponin assays
Newer troponin assays promise to be significantly more 
sensitive. These newer assays are in use in Europe and await 
approval from the US Food and Drug Administration before 
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Figure 2 Kaplan–Meier curves demonstrating survival from death or myocardial infarction stratified by the level of cTnT ($0.03 µg/L) or NT-proBNP (,1,371 ng/L).
Note: Reprinted from Am J Cardiol 103(1), McCann CJ, Glover BM, Menown IB, et al. Prognostic value of a mul timarker approach for patients presenting to hospital with 
acute chest pain, pages 22–28.36 Copyright © 2009 with permission from elsevier. 
Abbreviations: cTnT, cardiac troponin T; NT-proBNP, N-terminal prohormone of brain natriuretic peptide.
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they enter the market in the United States. They have been 
given the name “high-sensitivity” troponin (hs-cTn) assays, 
as they detect troponin at concentrations tenfold lower than 
the currently utilized assays. That said, these assays are based 
on the same biochemistry as traditional troponin assays and 
are likely just the next, rather than the final, step along the 
path of improving sensitivity. The increased sensitivity will 
force providers to rethink how these assays are used (Table 1). 
For example, simply detecting troponin with these assays 
will not be suggestive of myocardial ischemia as there will 
be a measurable troponin level in many, if not most, persons 
admitted to emergency departments as well as a significant 
proportion of the general population.12
In the DHS, the ability of a traditional and highly sensi-
tive cTnT assay to predict adverse events among a cohort 
of apparently healthy adults was compared. As noted 
above, ∼1% of apparently healthy patients had a detectable 
troponin level using a traditional troponin assay. The same 
samples were also analyzed using an hs-cTnT assay with 
a lower limit of detection of 3.0 ng/L and a 99th percentile 
URL of 1.4 ng/L. A detectable serum troponin was noted in 
25% of these subjects. Elevated hs-cTnT was independently 
associated with all-cause and cardiovascular mortality in a 
concentration-dependent manner (Figure 3).37
In emergency departments, hs-cTn measurements prom-
ise to change practice patterns. A large study by Reichlin 
et al was recently performed in which the effectiveness of 
four sensitive cTn assays were evaluated among 718 patients 
presenting to the emergency department complaining of 
symptoms consistent with AMI. The hs-cTn assays all per-
formed well when compared with a standard troponin assay, 
especially among patients presenting within a few hours of 
the onset of symptoms. Perhaps as importantly, the negative 
predictive value of these assays was quite high. In fact, when 
the 99th  percentile URL was used as a cutoff, the negative 
predictive value was 97%–99%.38
Table 1 A comparison of contemporary and highly sensitive troponin assays
Characteristic Current assays High sensitivity assays
General There is a variety of available troponin assays  
with unique test characteristics 
•  The test characteristics and cutoff values will  
vary from assay to assay
•  elevated levels uncommon in “apparently  
healthy adults”
There is a variety of available troponin assays with 
unique test characteristics 
•  Ten times more sensitive than conventional assays
•  elevated levels common in “apparently healthy” 
adults
•  “Cutoff” values will vary significantly across 
reference populations and with age
Diagnosis of AMI elevated troponin levels in the appropriate clinical 
setting are required for the diagnosis of AMI 
•  Serial measurements to detect a rise and fall 
in troponin concentration will likely remain an 
important part in the diagnosis of AMI
elevated troponin levels in the appropriate clinical 
setting are required for the diagnosis of AMI 
•  Significantly improved sensitivity, which translates to 
earlier detection
•  Reduced specificity
•  Serial measurements may still be required
exclusion of AMI The absence of a measurable troponin on a single 
blood draw is insufficient to exclude AMI
• The absence of a measurable troponin will likely 
exclude AMI
Non-cardiac disease Troponin levels may be elevated in a variety of  
pathological states, some of which constitute  
medical emergencies 
•  Aortic dissection
•  Pulmonary embolism
•  Shock
•  Heart failure
•  Chronic renal insufficiency
Troponin levels may be elevated in a variety of 
pathological states, some of which constitute medical 
emergencies 
•  Aortic dissection
•  Pulmonary embolism
•  Shock
•  Heart failure
•  Chronic renal insufficiency
Prognosis elevated serum troponin levels appear to be  
associated with a poor prognosis 
•  especially among hospitalized patients
elevated serum troponin levels appear to be associated 
with a poor prognosis 
•  May prove true among “apparently healthy 
outpatients”
Pitfalls associated with the  
elderly
Limitations 
•  Few studies evaluate an elderly population
Limitations 
•  Better studied in the elderly
•  Troponin levels “measurable” in the majority of 
elderly patients
•  Age specific “cutoff” values may be needed
Note: Data from Mohammed and Januzzi,51 and Korley and Jaffe.52
Abbreviation: AMI, acute myocardial infarction.
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High sensitivity cTn assays  
and the elderly
High sensitivity cTn assays will detect troponin in a substan-
tial number of asymptomatic elderly persons. In the DHS, 
age was found to be an independent predictor of a measurable 
hs-cTnT among asymptomatic adults.37 In an Italian cohort 
of community dwelling subjects aged 65–84 years, circulat-
ing levels of hs-cTnT were detected in 18% of the females 
and 41% of the males. Correlation with echocardiographic 
data indicated an association between left ventricular mass, 
mid-wall fractional shortening, and diastolic dysfunction.39 
Eggers et al evaluated troponin in 940 elderly men, 379 of 
whom had an established diagnosis of coronary artery disease 
and 561 of whom did not. Using an hs-cTnT assay with a 
measureable range (3.0–10,000 ng/L), a detectable troponin 
level was found in 92.8% of the patients.40 In another study, 
among patients .70 years old, the same group noted that 
hs-cTnT levels increased gradually with time and were on 
average 45% higher in the same patient after five years.41
Elderly persons presenting to emergency departments 
are also commonly found to have measurable troponin lev-
els using hs-cTn assays. Menacer et al42 evaluated troponin 
levels among 362 patients presenting to an emergency 
department without chest pain or signs of CVD. They used 
four hs-cTn assays including an hs-cTnT assay (lower 
limit of  quantification 13 ng/L) and three different hs-cTnI 
assays (lower limit of quantification 32, 40, and 30 ng/L). 
As expected, the hs-cTnT proved the most sensitive assay, 
detecting a measurable troponin level in 81% of the patients. 
The hs-cTnI assays proved less sensitive, detecting troponin 
in 15%–56% of this cohort.42 It will be impossible using 
high-sensitivity assays to assign a working diagnosis of AMI 
using only a serum troponin concentration, especially among 
elderly patients.
Copeptin
Arginine vasopressin is released from the neurohypophysis in 
response to changes in plasma osmolality and is involved in 
osmoregulation and cardiovascular homeostasis. Activation 
of the arginine vasopressin system is part of the endogenous 
response to stress, such as is encountered in the setting of 
AMI. Vasopressin degrades rapidly in circulation and has not 
been found to be useful as a biomarker. Instead,  copeptin, 
the more stable C-terminal fragment of provasopressin, 
has emerged as a promising surrogate for vasopressin in 
the characterization of the role of the arginine–vasopressin 
system in CVD. It has been hypothesized that the addition 
of copeptin levels to a diagnostic strategy for AMI might 
increase sensitivity and specificity. Reichlin et al43 used a 
conventional cTnT assay and a novel copeptin assay to risk 
stratify 492 patients presenting to an emergency department 
with symptoms suggestive of AMI. They found that copep-
tin levels were elevated very early in relation to the onset 
of symptoms and when compared with cTnT (Figure 4). 
Furthermore, when cTnT and copeptin measurements were 
evaluated in combination, improved diagnostic sensitivity 
for AMI was noted. This was true when the combination 
was compared to either assay alone, or the combination of 
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cTnT and CK-MB. Of equal importance, the combination of 
cTnT and copeptin was very effective in identifying patients 
without AMI (negative predictive value 99.7%).43
Growth-differentiation factor-15
Growth-differentiation factor (GDF)-15 is a member of the 
transforming growth factor-B cytokine superfamily. While 
GDF-15 is weakly expressed in most tissues under physio-
logical conditions, its expression levels increase in response 
to pathological stress associated with inflammation or tissue 
injury. CVD and AMI are known to be inflammatory states.44 
GDF-15 concentrations are elevated in AMI and in chronic 
HF. In both cases, these elevations have been associated with 
a subsequent increase in mortality.45–48 Recently, GDF-15 
was one of several biomarkers evaluated among a group 
of patients admitted with chest pain and an “undetectable” 
 troponin. The study enrolled 1,247 patients, all of whom were 
admitted with concern for AMI, but who had undetectable 
serum cTnT levels measured by a conventional assay. The 
authors found that in this low risk cohort, a GDF-15 level 
of .1800 ng/L was associated with an increased risk of death 
or myocardial infarction on follow-up.49
Conclusion
The practice of cardiovascular medicine has been for-
ever changed by the ability to measure biomarkers. 
Troponin measurements have become an integral part 
of contemporary diagnostic and patient management 
algorithms. The  current generation of troponin assays has 
been shown to better identify patients with AMI who are 
at a high risk for adverse events. Additionally, patients 
with an elevated troponin seem to benefit from an aggres-
sive therapeutic strategy. The prognostic power of other 
biomarkers such as NT-BNP has been established, but no 
link between these biomarkers and a therapeutic strategy 
has been established. Unfortunately, the studies upon 
which these conclusions were based enrolled relatively 
few elderly patients.
Research continues to find the next great biomarker for 
clinical practice and a few of the emerging candidates, as well 
as their potential utility, have been discussed in this paper. 
Elderly patients represent the largest portion of cardiovascu-
lar patients. There has been an increasing realization for the 
need to have algorithms that consider the patient’s age and 
other comorbidities rather than a one-size-fits-all approach 
to abnormal levels of biomarkers. With the increasing num-
ber of available biomarkers, the practice of medicine will 
depend more heavily on developing appropriate testing for 
all patients.
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